Antisense Therapeutics Ltd
ASX:ANP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Antisense Therapeutics Ltd
Other Current Assets
Antisense Therapeutics Ltd
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antisense Therapeutics Ltd
ASX:ANP
|
Other Current Assets
AU$66.5k
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
-9%
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Other Current Assets
AU$191.4k
|
CAGR 3-Years
4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Other Current Assets
AU$19.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Other Current Assets
AU$9.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Other Current Assets
AU$6.4m
|
CAGR 3-Years
126%
|
CAGR 5-Years
118%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Other Current Assets
AU$3.2m
|
CAGR 3-Years
149%
|
CAGR 5-Years
240%
|
CAGR 10-Years
N/A
|
|
Antisense Therapeutics Ltd
Glance View
Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is engaged in developing and commercializing antisense pharmaceuticals for unmet markets in rare diseases. The firm's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly. The firm's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The firm completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The firm is engaged in clinical development of ATL1102 in patients with Duchenne Muscular Dystrophy (DMD). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
See Also
What is Antisense Therapeutics Ltd's Other Current Assets?
Other Current Assets
66.5k
AUD
Based on the financial report for Jun 30, 2023, Antisense Therapeutics Ltd's Other Current Assets amounts to 66.5k AUD.
What is Antisense Therapeutics Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
-9%
Over the last year, the Other Current Assets growth was -94%. The average annual Other Current Assets growth rates for Antisense Therapeutics Ltd have been -48% over the past three years , -52% over the past five years , and -9% over the past ten years .
